Kimberly Whiton
Family · Troutman, NCNPI 1053914275
Payments from drug & device makers
Across 165 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$737
- GSK$624
- Lilly USA, LLC$224
- AbbVie$199
- Pfizer$166
- plus $938 from 20 others
What the payments were for
- Food & beverage$3,87898%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $1,085 |
| AstraZeneca | 18 | $737 |
| GSK | 20 | $624 |
| Lilly USA, LLC | 14 | $224 |
| AbbVie | 10 | $199 |
| Pfizer | 9 | $166 |
| Johnson & Johnson | 5 | $160 |
| Amgen | 8 | $152 |
| Abbott | 5 | $109 |
| Exact Sciences | 4 | $72 |
| Merck | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| Tolmar, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Vertex | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$251
- TRELEGY ELLIPTA$237
- Wegovy$230
- Saxenda$125
- AIRSUPRA$125
How this compares
$3,973 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $100,240 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $57,811 |
| MounjaroTirzepatide | 27 | $42,543 |
| JardianceEmpagliflozin | 31 | $30,534 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 54 | $17,068 |
| XareltoRivaroxaban | 16 | $16,689 |
| FarxigaDapagliflozin Propanediol | 14 | $14,931 |
| TrulicityDulaglutide | 12 | $13,363 |
| EliquisApixaban | 12 | $10,570 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 41 | $9,126 |
| Lagevrio (Eua)Molnupiravir | 15 | $7,798 |
| Rosuvastatin Calcium | 182 | $2,568 |
| Omega-3 Acid Ethyl Esters | 13 | $2,160 |
| Levothyroxine Sodium | 169 | $1,956 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,085 | $100,24052 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $624 | $84,004156 claims |
| Lilly USA, LLCMounjaro, Trulicity | $224 | $55,90639 claims |
| Boehringer IngelheimJardiance | $30 | $30,53431 claims |
| Johnson & JohnsonXarelto | $160 | $16,68916 claims |
| AstraZenecaFarxiga | $737 | $14,93114 claims |
| PfizerEliquis | $166 | $10,57012 claims |
| MerckLagevrio (Eua) | $53 | $7,79815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Troutman
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.